nifurtimox and Fever

nifurtimox has been researched along with Fever* in 2 studies

Reviews

1 review(s) available for nifurtimox and Fever

ArticleYear
Bug Smash, Bug Splash: A Case Report of an Unusual Transmission of American Trypanosomiasis with a Brief Review of the Literature.
    The American journal of case reports, 2016, Dec-29, Volume: 17

    BACKGROUND Chagas disease is a chronic parasitosis transmitted by the inoculation of infected triatomine feces into wounds or conjunctival sac, transfusion, congenitally, organ transplantation, and ingestion of contaminated food. The disease is classified into an acute and chronic phase; the latter is a life-long infection that can be asymptomatic or progress to cardiac or digestive complications. CASE REPORT We report a case of acute-phase Chagas disease, transmitted by the splash of gut content from an infected triatomine into the conjunctival mucosa. CONCLUSIONS The diagnosis of Chagas disease is made by the direct visualization of the parasite in blood smears during the acute phase of the disease; during the chronic phase of the disease the diagnosis is made by the detection of IgG antibodies. Parasitological cure can be achieved in up to 80% of the cases in acute phase of the disease, in contrast with less than 30% during the chronic phase.

    Topics: Adult; Animals; Chagas Disease; Edema; Fever; Headache; Humans; Male; Neglected Diseases; Nifurtimox; Treatment Outcome; Triatominae; Trypanocidal Agents; Trypanosoma cruzi

2016

Trials

1 trial(s) available for nifurtimox and Fever

ArticleYear
Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
    Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683

    Human African trypanosomiasis (HAT; sleeping sickness) caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment options for patients with second-stage disease are toxic, ineffective, or impractical. We assessed the efficacy and safety of nifurtimox-eflornithine combination therapy (NECT) for second-stage disease compared with the standard eflornithine regimen.. A multicentre, randomised, open-label, active control, phase III, non-inferiority trial was done at four HAT treatment centres in the Republic of the Congo and the Democratic Republic of the Congo. Patients aged 15 years or older with confirmed second-stage T b gambiense infection were randomly assigned by computer-generated randomisation sequence to receive intravenous eflornithine (400 mg/kg per day, every 6 h; n=144) for 14 days or intravenous eflornithine (400 mg/kg per day, every 12 h) for 7 days with oral nifurtimox (15 mg/kg per day, every 8 h) for 10 days (NECT; n=143). The primary endpoint was cure (defined as absence of trypanosomes in body fluids and a leucocyte count

    Topics: Administration, Oral; Adult; Animals; Congo; Democratic Republic of the Congo; Drug Administration Schedule; Drug Therapy, Combination; Eflornithine; Female; Fever; Follow-Up Studies; Humans; Infections; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Nifurtimox; Safety; Seizures; Treatment Outcome; Trypanocidal Agents; Trypanosoma brucei gambiense; Trypanosomiasis, African

2009